Metabolic and Microenvironment Patterns in Metastatic Pancreatic Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study examines how metabolic processes and the tumor microenvironment in pancreatic ductal adenocarcinoma interact in primary tumors and metastatic sites, as well as in circulating biomarkers. It collects tissue biopsies and blood samples to identify biomarkers and potential targets linked to treatment outcomes. The goal is to uncover vulnerabilities that could help predict how well therapies work or guide future treatment choices. The study centers on stromal cell prevalence and metabolic reprogramming as key features of PDAC. It is conducted at Institut Paoli-Calmettes with adults eligible for chemotherapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age \> 18 years
2. Signed written informed consent specific to the PROMETAP study
3. Affiliation with a social security system
4. Treatment and follow-up performed at the Institut Paoli-Calmettes
5. Metastatic PDAC requiring biopsy as part of routine care (group1 and 2)
6. Prior treatment:

   * No previous chemotherapy for the "initial" group
   * No prior chemotherapy in the metastatic setting for the "Metastatic Relapse" group
7. Eligible for chemotherapy (ECOG \< 2)

Non-Inclusion Criteria:

1. Contraindication to biopsy of the pancreatic tumor or a hepatic or pulmonary metastasis (group 1 and 2)
2. Absence of a metastasis accessible to biopsy (group1 and 2)
3. Concurrent treatment for another active cancer
4. Pregnant or breastfeeding women
5. Patients in emergency situations

5\. Adult individuals under legal protection (guardianship, trusteeship, judicial protection) or unable to provide informed consent

Where it's running

• Institut Paoli-Calmettes
  Marseille, France Recruiting

Study contacts

• Study coordinator: Jihane PAKRADOUNI
• Email: drci.up@ipc-unicancer.fr
• Phone: +334 91223778

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Zoldonrasib plus Daraxonrasib vs Gemcitabine and Nab-Paclitaxel as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This study tests whether two investigational RAS inhibitors together can improve outcomes compared with standard chemotherapy in adults with newly diagnosed metastatic pancreatic cancer carrying the KRAS G12D mutation.

  Recruiting at 6 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 5 other locations · NCT07805954

• Zoldonrasib + chemotherapy vs placebo + chemotherapy as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This trial tests whether adding zoldonrasib to standard chemotherapy helps people with newly diagnosed metastatic KRAS G12D pancreatic cancer.

  Recruiting at 25 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 24 other locations · NCT07621718

• Atebimetinib plus gemcitabine and nab‑paclitaxel as first‑line treatment for metastatic pancreatic cancer

  This trial will test whether adding the MAPK pathway drug atebimetinib to gemcitabine and nab‑paclitaxel helps people with newly diagnosed metastatic pancreatic ductal adenocarcinoma live longer.

  Recruiting at 76 sites Phase 3 Immuneering Corporation · Huntsville, Alabama and 75 other locations · NCT07562152

• Daraxonrasib alone or with gemcitabine and nab-paclitaxel for first-line metastatic pancreatic cancer

  This trial will see if daraxonrasib, alone or with gemcitabine and nab-paclitaxel, helps people with newly diagnosed metastatic pancreatic cancer live longer or slow tumor growth compared with standard gemcitabine and nab-paclitaxel.

  Recruiting at 61 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 81 other locations · NCT07491445

• OMTX705 added to standard chemo with or without tislelizumab for advanced pancreatic cancer

  This trial will try adding OMTX705 to gemcitabine/nab‑paclitaxel, with or without tislelizumab, to see if it is safe and might help people with advanced or metastatic pancreatic cancer.

  Recruiting at 6 sites Phase 1 Oncomatryx Biopharma S.L. · Boston, Massachusetts and 6 other locations · NCT07377045

• TTFields plus modFOLFIRINOX for metastatic pancreatic adenocarcinoma

  This trial will test whether adding Tumor Treating Fields (TTFields) to modFOLFIRINOX chemotherapy is safe, tolerable, and helpful for adults with metastatic pancreatic ductal adenocarcinoma.

  Recruiting Phase 1/2 Clinica Universidad de Navarra, Universidad de Navarra · Pamplona, Navarre and 4 other locations · NCT07284277

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.